Klijn J G, Bontenbal M
Academisch Zickenhuis Rotterdam-Daniel den Hoed Kliniek, afd. Interne Oncologie.
Ned Tijdschr Geneeskd. 1998 Jan 17;142(3):113-7.
Additional advantages of hormone suppletion therapy (HST) in women with climacteric complaints are the reduced risks of development of cardiovascular disease and osteoporosis. A disadvantage is the enhanced risk of breast cancer. More and more women with a treated primary breast cancer nowadays have a relatively favourable prognosis; they might also profit by HST, especially if chemotherapy for breast cancer has led to an early menopause. Recent pilot studies of the connection between HST and recurrence of breast cancer are inadequate as to methodology and size to permit definite conclusions. There are numerous arguments for a connection between exposure to oestrogens and development of breast cancer. As long as it has not been demonstrated that HST does not lead to enhanced risk of breast cancer recurrence, the general recommendation should be not to administer HST to patients with treated breast carcinoma.
激素补充疗法（HST）对于有更年期症状的女性的其他益处在于降低了患心血管疾病和骨质疏松症的风险。一个缺点是患乳腺癌的风险增加。如今，越来越多接受过原发性乳腺癌治疗的女性预后相对良好；她们也可能从激素补充疗法中获益，尤其是如果乳腺癌化疗导致了早期绝经的情况。近期关于激素补充疗法与乳腺癌复发之间联系的初步研究在方法和规模上都不足以得出明确结论。有大量论据支持雌激素暴露与乳腺癌发生之间存在关联。只要尚未证明激素补充疗法不会导致乳腺癌复发风险增加，一般建议就不应给接受过乳腺癌治疗的患者使用激素补充疗法。
